Carregant...
Phase I Studies of Acebilustat: Biomarker Response and Safety in Patients with Cystic Fibrosis
There is a significant unmet need for safe and effective anti‐inflammatory treatment for cystic fibrosis. The aim of this study was to evaluate the safety of acebilustat, a leukotriene A4 hydrolase inhibitor, and its effect on inflammation biomarkers in patients with cystic fibrosis. Seventeen patie...
Guardat en:
| Publicat a: | Clin Transl Sci |
|---|---|
| Autors principals: | , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
John Wiley and Sons Inc.
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5351012/ https://ncbi.nlm.nih.gov/pubmed/27806191 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cts.12428 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|